The Role of Pharmacogenomics Studies for Precision Medicine Among Ethiopian Patients and Their Clinical Implications: A Scoping Review

References

• Radouani F, Zass L, Hamdi Y, et al. A review of clinical pharmacogenetics Studies in African populations. Per Med. 2020;17(2):155–170. doi:10.2217/pme-2019-0110
   PubMed Web of Science ®Google Scholar
• Davis BH, Limdi NA. Translational pharmacogenomics: discovery, evidence synthesis and delivery of race-conscious medicine. Clin Pharmacol Ther. 2021;110(4):909–925. doi:10.1002/cpt.2357
   PubMed Web of Science ®Google Scholar
• Khan A, Abbas M, Verma S, et al. Genetic variants and drug efficacy in tuberculosis: A step toward personalized therapy. Glob Med Genet. 2022;9(2):90–96. doi:10.1055/s-0042-1743567
   PubMedGoogle Scholar
• Ross CJ, Carleton B, Warn DG, Stenton SB, Rassekh SR, Hayden MR. Genotypic approaches to therapy in children: a national active surveillance network (GATC) to study the pharmacogenomics of severe adverse drug reactions in children. Ann N Y Acad Sci. 2007;1110(1):177–192. doi:10.1196/annals.1423.020
   PubMedGoogle Scholar
• RCoP, and Society BP. Personalised prescribing using pharmacogenomics to improve patient outcomes; 2022.
   Google Scholar
• Cacabelos R, Naidoo V, Corzo L, Cacabelos N, Carril JC. Genophenotypic factors and pharmacogenomics in adverse drug reactions. Int J Mol Sci. 2021;22(24):13302. doi:10.3390/ijms222413302
   PubMed Web of Science ®Google Scholar
• Abdela OA, Bhagavathula AS, Gebreyohannes EA, Tegegn HG. Ethiopian health care professionals’ knowledge, attitude, and interests toward pharmacogenomics. Pharmgen Pers Med. 2017;10:279–285. doi:10.2147/PGPM.S145336
   PubMed Web of Science ®Google Scholar
• Nebert DW. Pharmacogenetics and pharmacogenomics: why is this relevant to the clinical geneticist? Clin Genet. 1999;56(4):247–258. doi:10.1034/j.1399-0004.1999.560401.x
   PubMed Web of Science ®Google Scholar
• Oh M, Park S, Lee S, et al. DRIM: A web-based system for investigating drug response at the molecular level by condition-specific multi-omics data integration. Front Genet. 2020;11:564792. doi:10.3389/fgene.2020.564792
   PubMed Web of Science ®Google Scholar
• Daly AK. Pharmacogenetics: a general review on progress to date. Br Med Bull. 2017;124(1):65–79. doi:10.1093/bmb/ldx035
   PubMed Web of Science ®Google Scholar
• Weinshilboum RM, Wang L. Pharmacogenetics and pharmacogenomics: development, science, and translation. Annu Rev Genomics Hum Genet. 2006;7(1):223–245. doi:10.1146/annurev.genom.6.080604.162315
   PubMedGoogle Scholar
• Marshall A. Laying the foundations for personalized medicines. Nature Biotechnol. 1998;16(S2):6–8. doi:10.1038/5138
   Google Scholar
• Roden DM, McLeod HL, Relling MV, et al. Pharmacogenomics. Lancet. 2019;394(10197):521–532. doi:10.1016/S0140-6736(19)31276-0
   PubMed Web of Science ®Google Scholar
• Malsagova KA, Butkova TV, Kopylov AT, et al. Pharmacogenetic testing: a tool for personalized drug therapy optimization. Pharmaceutics. 2020;12(12):1240. doi:10.3390/pharmaceutics12121240
   PubMed Web of Science ®Google Scholar
• Aneesh TPSSM, Jose A, Chandran L, Mary Zachariah S, Zachariah SM. Pharmacogenomics: The right drug to the right person. J Clin Med Res. 2009;1(4):191–194. doi:10.4021/jocmr2009.08.1255
   PubMedGoogle Scholar
• Russo R, Capasso M, Paolucci P, Iolascon A. Pediatric pharmacogenetic and pharmacogenomic studies: the current state and future perspectives. Eur J Clin Pharmacol. 2011;67(Suppl S1):17–27. doi:10.1007/s00228-010-0931-1
   PubMedGoogle Scholar
• Sindelar RD. Crommelin RDSaBM. In: Daan JA, editor. Pharmaceutical Biotechnology Fundamentals and Applications. Switzerland Springer Nature; 2019:192–237 p.
   Google Scholar
• Pirmohamed M. Personalized pharmacogenomics: predicting efficacy and adverse drug reactions. Annu Rev Genomics Hum Genet. 2014;15(1):349–370. doi:10.1146/annurev-genom-090413-025419
   PubMedGoogle Scholar
• Lauschke VM, Milani L, Ingelman-Sundberg M. Pharmacogenomic biomarkers for improved drug therapy-recent progress and future developments. AAPS J. 2017;20(1):4. doi:10.1208/s12248-017-0161-x
   PubMed Web of Science ®Google Scholar
• Suarez-Kurtz G, Aklillu E, Saito Y, Somogyi AA. Conference report: pharmacogenomics in special populations at WCP2018. Br J Clin Pharmacol. 2019;85(3):467–475. doi:10.1111/bcp.13828
   PubMed Web of Science ®Google Scholar
• Admas T, Banjaw A. Healthcare professionals’ knowledge, attitudes and future expectations towards personalized medicine. Per Med. 2021;18(5):483–490. doi:10.2217/pme-2020-0185
   PubMedGoogle Scholar
• Yow HY, Hamzah S, Abdul Rahim N, Suppiah V. Pharmacogenomics of response to statin treatment and susceptibility to statin-induced adverse drug reactions in Asians: A scoping review. Asian Biomed (Res Rev News). 2023;17(3):95–114. doi:10.2478/abm-2023-0050
   PubMedGoogle Scholar
• Gc PM, McInerney P, Munn Z, Tricco A, Khalil H. Guidance for the Conduct of JBI Scoping Reviews. In: Edoardo Aromataris ZM, editor. Joanna Briggs Institute Reviewer’s Manual. The Joanna Briggs Institute; 2017.
   Google Scholar
• Peters MDJ, Marnie C, Tricco AC, et al. Updated methodological guidance for the conduct of scoping reviews. JBI Evid Synth. 2020;18(10):2119–2126. doi:10.11124/JBIES-20-00167
   PubMedGoogle Scholar
• Tricco AC, Lillie E, Zarin W, et al. PRISMA extension for scoping reviews (PRISMA-ScR): Checklist and explanation. Ann Intern Med. 2018;169(7):467–473. doi:10.7326/M18-0850
   PubMed Web of Science ®Google Scholar
• Habtewold A, Amogne W, Makonnen E, et al. Long-term effect of efavirenz autoinduction on plasma/peripheral blood mononuclear cell drug exposure and CD4 count is influenced by UGT2B7 and CYP2B6 genotypes among HIV patients. J Antimicrob Chemother. 2011;66(10):2350–2361. doi:10.1093/jac/dkr304
   PubMed Web of Science ®Google Scholar
• Yimer G, Ueda N, Habtewold A, et al. Pharmacogenetic & pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patients. PLoS One. 2011;6(12):e27810. doi:10.1371/journal.pone.0027810
   PubMed Web of Science ®Google Scholar
• Yimer G, Amogne W, Habtewold A, et al. High plasma efavirenz level and CYP2B6*6 are associated with efavirenz-based HAART-induced liver injury in the treatment of naive HIV patients from Ethiopia: A prospective cohort study. Pharmacogenomics J. 2012;12(6):499–506. doi:10.1038/tpj.2011.34
   PubMed Web of Science ®Google Scholar
• Habtewold A, Amogne W, Makonnen E, et al. Pharmacogenetic and pharmacokinetic aspects of CYP3A induction by efavirenz in HIV patients. Pharmacogenomics J. 2013;13(6):484–489. doi:10.1038/tpj.2012.46
   PubMed Web of Science ®Google Scholar
• Ibrahim M. Pharmacokinetics of isoniazid in Ethiopian children with tuberculosis in relation to the N-acetyltransferase 2 (NAT2) genotype. Afr J Pharm Pharmacol. 2013;7(18):1124–1130. doi:10.5897/AJPP2012.0040
   Google Scholar
• Ngaimisi E, Habtewold A, Minzi O, et al. Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two sub-Saharan Africa populations. PLoS One. 2013;8(7):e67946. doi:10.1371/journal.pone.0067946
   PubMed Web of Science ®Google Scholar
• Abiy Habtewold EM, Amogne W, Yimer G, Aderaye G, Leif BJBEA. Is there a need to increase the dose of efavirenz during concomitant rifampicin-based antituberculosis therapy in sub-Saharan Africa? The HIV-TB pharmagene study. Pharmacogenomics. 2015;16(10):1047–1064
   PubMed Web of Science ®Google Scholar
• Habtewold A, Aklillu E, Makonnen E, et al. Long-term effect of rifampicin-based anti-tb regimen coadministration on the pharmacokinetic parameters of Efavirenz and 8-Hydroxy-Efavirenz in Ethiopian patients. J Clin Pharmacol. 2016;56(12):1538–1549. doi:10.1002/jcph.756
   PubMed Web of Science ®Google Scholar
• Petros Z, Lee MM, Takahashi A, et al. Genome-wide association and replication study of anti-tuberculosis drugs-induced liver toxicity. BMC Genomics. 2016;17(1):755. doi:10.1186/s12864-016-3078-3
   PubMedGoogle Scholar
• Petros Z, Lee MT, Takahashi A, et al. Genome-Wide association and replication study of hepatotoxicity induced by antiretrovirals alone or with concomitant anti-tuberculosis drugs. OMICS. 2017;21(4):207–216. doi:10.1089/omi.2017.0019
   PubMed Web of Science ®Google Scholar
• Petros Z, Kishikawa J, Makonnen E, Yimer G, Habtewold A, Aklillu E. HLA-B(*)57 allele is associated with concomitant anti-tuberculosis and antiretroviral drugs induced liver toxicity in Ethiopians. Front Pharmacol. 2017;8:90. doi:10.3389/fphar.2017.00090
   PubMed Web of Science ®Google Scholar
• Habtewold A, Aklillu E, Makonnen E, et al. Population pharmacokinetic model linking plasma and peripheral blood mononuclear cell concentrations of efavirenz and its metabolite, 8-Hydroxy-Efavirenz, in HIV Patients. Antimicrob Agents Chemother. 2017;61(8). doi:10.1128/AAC.00207-17.
   PubMed Web of Science ®Google Scholar
• Lo E, Zhong D, Raya B, et al. Prevalence and distribution of G6PD deficiency: implication for the use of primaquine in malaria treatment in Ethiopia. Malar J. 2019;18(1):340. doi:10.1186/s12936-019-2981-x
   PubMed Web of Science ®Google Scholar
• Ahmed JH, Makonnen E, Yimer G, et al. CYP2J2(*)7 Genotype Predicts Risk of Chemotherapy-Induced Hematologic Toxicity and Reduced Relative Dose Intensity in Ethiopian Breast Cancer Patients. Front Pharmacol. 2019;10:481. doi:10.3389/fphar.2019.00481
   PubMed Web of Science ®Google Scholar
• Ahmed JH, Makonnen E, Bisaso RK, et al. Population Pharmacokinetic, Pharmacogenetic, and Pharmacodynamic Analysis of Cyclophosphamide in Ethiopian Breast Cancer Patients. Front Pharmacol. 2020;11:406. doi:10.3389/fphar.2020.00406
   PubMed Web of Science ®Google Scholar
• Aklillu E, Zumla A, Habtewold A, et al. Early or deferred initiation of efavirenz during rifampicin-based TB therapy has no significant effect on CYP3A induction in TB-HIV infected patients. Br J Pharmacol. 2021;178(16):3294–3308. doi:10.1111/bph.15309
   PubMed Web of Science ®Google Scholar
• Mugusi S, Habtewold A, Ngaimisi E, et al. Impact of Population and Pharmacogenetics Variations on Efavirenz Pharmacokinetics and Immunologic Outcomes During Anti-Tuberculosis Co-Therapy: a Parallel Prospective Cohort Study in Two Sub-Sahara African Populations. Front Pharmacol. 2020;11:26. doi:10.3389/fphar.2020.00026
   PubMed Web of Science ®Google Scholar
• Chala A, Tadesse BT, Chaka TE, et al. Predictors of Efavirenz Plasma Exposure, Auto-Induction Profile, and Effect of Pharmacogenetic Variations among HIV-Infected Children in Ethiopia: a Prospective Cohort Study. J Pers Med. 2021;11(12):1303. doi:10.3390/jpm11121303
   PubMed Web of Science ®Google Scholar
• Tadesse WT, Mlugu EM, Shibeshi W, Degu WA, Engidawork E, Aklillu E. CYP3A and CYP2B6 Genotype Predicts Glucose Metabolism Disorder among HIV Patients on Long-Term Efavirenz-Based ART: a Case-Control Study. J Pers Med. 2022;12(7):1087. doi:10.3390/jpm12071087
   PubMed Web of Science ®Google Scholar
• Matimba A, Dhoro M, Dandara C. Is there a role of pharmacogenomics in Africa. Glob Health Epidemiol Genom. 2016;1(e9).
   Google Scholar
• Zhou Y, Ingelman‐Sundberg M, Lauschke VM. Worldwide distribution of Cytochrome P450 Alleles: A meta-analysis of population-scale sequencing projects. Clin Pharmacol Ther 2017;102(4):688–700. doi:10.1002/cpt.690
   PubMed Web of Science ®Google Scholar
• Hellenthal G, Bird N, Morris S. Structure and ancestry patterns of Ethiopians in genome-wide autosomal DNA. Hum Mol Genet. 2021;30(R1):R42–R48. doi:10.1093/hmg/ddab019
   PubMed Web of Science ®Google Scholar
• Lopez S, Tarekegn A, Band G, et al. Evidence of the interplay of genetics and culture in Ethiopia. Nat Commun. 2021;12(1):3581. doi:10.1038/s41467-021-23712-w
   PubMed Web of Science ®Google Scholar
• Cacabelos R, Cacabelos N, Carril JC. The role of pharmacogenomics in adverse drug reactions. Expert Rev Clin Pharmacol. 2019;12(5):407–442. doi:10.1080/17512433.2019.1597706
   PubMed Web of Science ®Google Scholar
• Zhang F, Finkelstein J. Inconsistency in race and ethnic classification in pharmacogenetics studies and its potential clinical implications. Pharmg Pers Med. 2019;12:107–123. doi:10.2147/PGPM.S207449
   Web of Science ®Google Scholar
• Shao Q, Mao X, Zhou Z, Huai C, Li Z. Research progress of pharmacogenomics in drug-induced liver injury. Front Pharmacol. 2021;12:735260. doi:10.3389/fphar.2021.735260
   PubMed Web of Science ®Google Scholar
• Pirmohamed M. Pharmacogenomics: current status and future perspectives. Nat Rev Genet. 2023;24(6):350–362. doi:10.1038/s41576-022-00572-8
   PubMed Web of Science ®Google Scholar